Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis
Phase of Trial: Phase I
Latest Information Update: 15 Jun 2016
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- Acronyms RESI
- 10 Jun 2017 Biomarkers information updated
- 02 Jun 2016 Patients are receiving Rebif/Avonex now. Thus changes in purpose, primary end points and treatment.
- 02 Jun 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017.